Skip to main content
SpringerLink
Log in

Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses

  • Short Communication
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background

When children with attention-deficit/hyperactivity disorder (ADHD) are treated with stimulant medication, the dose is established clinically by dose adjustment over time. Little is known about children who are not adequately treated when they reach a designated maximum dose, or the consequences of exceeding this dose.

Objective

The aim of this study was to determine the characteristics of and side effects observed in children optimised to high dose (HD) versus regular dose (RD) stimulants.

Method

Children treated by one paediatrician (AP) in Western Sydney, Australia with HD stimulants (n = 52) were identified using an electronic database; controls on RD stimulant (n = 118) were matched by prescription date with the cases’ first HD prescription. HD was defined as methylphenidate > 2 mg/kg/day or > 108 mg/day; dexamphetamine > 1 mg/kg/day or > 50 mg/day; lisdexamfetamine > 70 mg/day. In all children, the dose was adjusted over time to optimise the clinical response. Clinical characteristics, anthropometric measures, reported side effects and reasons for dose changes were extracted from the clinical charts by LR, VS and CS. The HD and RD cohorts were compared using chi-square for categorical data and t tests for continuous data.

Results

The HD cohort included more boys (88% vs 75%, p = 0.041) and more oppositional defiant disorder (83% vs 55%, p = 0.001). They started stimulants younger (6.40 ± 1.67 vs 8.28 ± 2.77 years, p < 0.001) and had more growth attenuation (Δ height z-score − 0.41 ± 0.55 vs − 0.09 ± 0.58, p = 0.001; Δ weight z-score  − 0.56 ± 0.82 vs − 0.18 ± 0.66, p = 0.002). The growth attenuation mainly occurred before the dose reached the HD range. Diminishing stimulant effectiveness was the commonest reason for a dose increase in either cohort, the most prominent recurring symptoms being persistent anger/aggression in the HD and poor concentration in the RD cohort. The commonest reason for dose reduction in the HD cohort was that a dose increase gave no added benefit; dose reduction or change of drug due to subdued/depressed behaviour was more frequent in RD children. Apart from growth attenuation, no serious complications were reported in the HD group.

Conclusions

In this preliminary study, dose adjustment over time in some patients meant using higher doses than those generally recommended. These children experienced more growth attenuation but recorded no other significant treatment complications. Determining the dose purely on clinical grounds by careful dose adjustment over time appears reasonable, but more data on this issue is required to clarify the efficacy and tolerability of exceeding the recommended doses of stimulants when treating ADHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2018.

  2. Davy T, Rodgers CL. Stimulant medication and short attention span: a clinical approach. J Dev Behav Pediatr. 1989;10(6):313–8.

    Article  CAS  Google Scholar 

  3. Ching C, Eslick GD, Poulton AS. Evaluation of methylphenidate safety and maximum-dose titration rationale in attention-deficit/hyperactivity disorder: a meta-analysis. JAMA Pediatr. 2019.

  4. NSW Ministry of Health. Criteria for the diagnosis and management of attention deficit hyperactivity disorder in children and adolescents (TG181/9). 2016.

  5. Pelham W, Milich R, Murphy D, Murphy H. Normative data on the IOWA Conners teacher rating scale. J Clin Child Psychology. 1989;18(3):259–62.

    Article  Google Scholar 

  6. Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40(2):188–96.

    Article  CAS  Google Scholar 

  7. Poulton A, Briody J, McCorquodale T, et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? A prospective longitudinal study. Int J Pediatr Endocrinol. 2012;2012(1):30.

    Article  Google Scholar 

  8. Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. Int Clin Psychopharmacol. 2016;31(2):93–9.

    Article  Google Scholar 

  9. Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health. 2003;39(3):180–5.

    Article  CAS  Google Scholar 

  10. Carton L, Dondaine T, Deheul S, et al. Supervised off-label prescribing of methylphenidate in adult ADHD. Encephale. 2018.

  11. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science. 1977;198(4323):1274–6.

    Article  CAS  Google Scholar 

  12. Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics. 2010;126(4):e796–806.

    Article  Google Scholar 

  13. Poulton AS, Paterson R. Stimulant prescribing for attention deficit hyperactivity disorder (ADHD): what guides clinicians in their choice of an upper limit for dose titration? Australas Psychiatry. 2020:1039856220905298.

  14. Dravland JE. Effective stimulant dosing in attention-deficit/hyperactivity disorder. JAMA Pediatr. 2019;173(12):1210–11.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, Nepean Hospital, PO Box 63, Penrith, NSW, 2751, Australia

    Lindsey Ross & Veena Sapre

  2. Faculty of Health Sciences, The University of Sydney, Sydney, NSW, Australia

    Christina Stanislaus

  3. Brain Mind Centre Nepean, The University of Sydney, Penrith, NSW, Australia

    Alison S. Poulton

Authors
  1. Lindsey Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veena Sapre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christina Stanislaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alison S. Poulton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alison S. Poulton.

Ethics declarations

Conflicts of interest

Dr Poulton has received speakers bureau honoraria, CME activity, conference support and advisory panel payments from Shire; Dr Ross, Dr Sapre and Ms Stanislaus report no financial relationships with commercial interests.

Funding

This research was unfunded.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ross, L., Sapre, V., Stanislaus, C. et al. Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses. CNS Drugs 34, 643–649 (2020). https://doi.org/10.1007/s40263-020-00725-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-020-00725-5

Search

Navigation